Work led by Dr. Analia Bortolozzi has shown a possible new drug target to alleviate early deficiencies in dopamine function in Parkinson's disease. The results have been confirmed in mice and elderly non-human primates, paving the way to be transferred to humans.
Researchers from Rush University Medical Center, Neurodegenerative Diseases Research Group (Vall d'Hebron Research Institute) and n-Life Therapeutics participate in this study.
Alarcón-Arís D, Pavia-Collado R, Miquel-Rio L, Coppola-Segovia V, Ferrés-Coy A, Ruiz-Bronchal E, Galofré M, Paz V, Campa L, Revilla R, Montefeltro A, Kordower JH, Vila M, Artigas F, Bortolozzi A. Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys. EBioMedicine. 2020 Sep;59:102944. doi: 10.1016/j.ebiom.2020.102944. Epub 2020 Aug 15. PMID: 32810825; PMCID: PMC7452525.